Literature DB >> 12378307

Short and long period optimization of drug doses in the treatment of AIDS.

Marco A L Caetano1, Takashi Yoneyama.   

Abstract

Numerical optimization techniques are useful in solving problems of computing the best inputs for systems described by mathematical models and when the objectives can be stated in a quantitative form. This work concerns the problem of optimizing the drug doses in the treatment of AIDS in terms of achieving a balance between the therapeutic response and the side effects. A mathematical model describing the dynamics of HIV viruses and CD4 cells is used to compute the short term optimal drug doses in the treatments of patients with AIDS by a direct method of optimization using a cost function of Bolza type. The model parameters were fitted to actual published clinical data. In order to simplify the numerical procedures, the control law is expressed as a series and the sub-optimal control is obtained by truncating the higher terms. When the patient reaches a clinically satisfactory state, the LQR - Linear Quadratic Regulator technique is used to determine the long period maintenance doses for the drugs. The doses computed using the LQR technique tend to be smaller than equivalent constant-dose therapy in terms of increase in the counts of CD4+T cells and reduction of the density of free viruses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12378307     DOI: 10.1590/s0001-37652002000300002

Source DB:  PubMed          Journal:  An Acad Bras Cienc        ISSN: 0001-3765            Impact factor:   1.753


  2 in total

1.  Optimal control of HIV dynamic using embedding method.

Authors:  H Zarei; A V Kamyad; M H Farahi
Journal:  Comput Math Methods Med       Date:  2011-04-18       Impact factor: 2.238

2.  Quantifying the treatment efficacy of reverse transcriptase inhibitors: new analyses of clinical data based on within-host modeling.

Authors:  Romulus Breban; Sonia Napravnik; James Kahn; Sally Blower
Journal:  BMC Public Health       Date:  2009-11-18       Impact factor: 3.295

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.